NCT06327100View on ClinicalTrials.gov

Open Label Phase 2 Study of Tasquinimod in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PV MF), or Post-Essential Thrombocytosis Myelofibrosis (Post-ET MF)

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

1

Participants

Timeline

Start Date

August 1, 2024

Primary Completion Date

May 1, 2029

Study Completion Date

May 1, 2031

Conditions
Primary MyelofibrosisPost-polycythemia Vera MyelofibrosisPost-Essential Thrombocytosis Myelofibrosis
Interventions
DRUG

Ruxolitinib

Given by PO

DRUG

Tasquinimod

Given by PO

Trial Locations (1)

77030

MD Anderson Cancer Center, Houston

Sponsors

Collaborators (1)

Active Biotech AB
All Listed Sponsors
collaborator

Active Biotech AB

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER